RxDoctor Payments Data

Heather Ludwig-Akers

Family Medicine · Vincennes, INNPI 1134352339

Payments from drug & device makers

$8,813in general payments, 2019–2025

Across 674 payments — averaging $13.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Amgen$1K
  • Pfizer$783
  • Lilly USA, LLC$729
  • Bayer$287
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$8,813100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,813 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$60,240
Medicare patients
244
Services billed
1,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$58,645
EliquisApixaban46$39,098
VraylarCariprazine Hcl24$36,887
JardianceEmpagliflozin22$23,676
MounjaroTirzepatide20$21,681
GemtesaVibegron20$16,739
Repatha SureclickEvolocumab27$16,542
FarxigaDapagliflozin Propanediol12$14,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,672
XareltoRivaroxaban14$13,687
Breo ElliptaFluticasone/Vilanterol35$13,441
Praluent PenAlirocumab19$9,001
Janumet XrSitagliptin Phos/Metformin Hcl13$8,103
TrintellixVortioxetine Hydrobromide13$6,332
DuleraMometasone/Formoterol11$3,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,350$58,64555 claims
PfizerEliquis, Premarin, Paxlovid$783$42,86969 claims
AbbVieVraylar$1,620$36,88724 claims
GSKTrelegy Ellipta, Breo Ellipta$107$28,11357 claims
Boehringer IngelheimJardiance$59$23,67622 claims
Lilly USA, LLCMounjaro$729$21,68120 claims
Sumitomo Pharma America, Inc.Gemtesa$71$16,73920 claims
AstraZenecaFarxiga$262$14,94112 claims
Johnson & JohnsonXarelto$13$13,68714 claims
MerckJanumet Xr, Dulera$137$11,67924 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$281$6,33213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Vincennes

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →